Rebecca (Ribka) Berhanu, MD
Postdoctoral Fellow
Boston University School of Public Health
Dept of Global Health

Transmission of drug-resistant tuberculosis in a South African city with a high prevalence of HIV infection
08/04/2020 - 07/31/2025 (PI)
NIH/National Institute of Allergy & Infectious Diseases


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Masuku SD, Berhanu R, Van Rensburg C, Ndjeka N, Rosen S, Long L, Evans D, Nichols BE. Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis. Int J Tuberc Lung Dis. 2020 04 01; 24(4):376-382.View Related Profiles. PMID: 32317060
  2. Jamieson L, Evans D, Berhanu R, Ismail N, Aucock S, Wallengren K, Long L. Data quality of drug-resistant tuberculosis and antiretroviral therapy electronic registers in South Africa. BMC Public Health. 2019 Dec 05; 19(1):1638.View Related Profiles. PMID: 31805982; DOI: 10.1186/s12889-019-7965-9;
  3. Berry KM, Rodriguez CA, Berhanu RH, Ismail N, Mvusi L, Long L, Evans D. Treatment outcomes among children, adolescents, and adults on treatment for tuberculosis in two metropolitan municipalities in Gauteng Province, South Africa. BMC Public Health. 2019 Jul 22; 19(1):973.View Related Profiles. PMID: 31331311
  4. van Rensburg C, Berhanu R, Hirasen K, Evans D, Rosen S, Long L. Cost outcome analysis of decentralized care for drug-resistant tuberculosis in Johannesburg, South Africa. PLoS One. 2019; 14(6):e0217820.View Related Profiles. PMID: 31170207; DOI: 10.1371/journal.pone.0217820;
  5. Sineke T, Evans D, Schnippel K, van Aswegen H, Berhanu R, Musakwa N, Lönnmark E, Long L, Rosen S. The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa. Health Qual Life Outcomes. 2019 May 31; 17(1):94.View Related Profiles. PMID: 31151398
  6. Berhanu RH, Schnippel K, Kularatne R, Firnhaber C, Jacobson KR, Horsburgh CR, Lippincott CK. Discordant rifampicin susceptibility results are associated with Xpert® MTB/RIF probe B and probe binding delay. Int J Tuberc Lung Dis. 2019 03 01; 23(3):358-362.View Related Profiles. PMID: 30940300
  7. Evans D, Sineke T, Schnippel K, Berhanu R, Govathson C, Black A, Long L, Rosen S. Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa. BMC Health Serv Res. 2018 Dec 17; 18(1):973.View Related Profiles. PMID: 30558670; DOI: 10.1186/s12913-018-3762-x;
  8. Berhanu RH, David A, da Silva P, Shearer K, Sanne I, Stevens W, Scott L. Performance of Xpert MTB/RIF, Xpert Ultra, and Abbott RealTime MTB for Diagnosis of Pulmonary Tuberculosis in a High-HIV-Burden Setting. J Clin Microbiol. 2018 12; 56(12).View Related Profiles. PMID: 30305387
  9. Hirasen K, Berhanu R, Evans D, Rosen S, Sanne I, Long L. High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa. PLoS One. 2018; 13(10):e0205463.View Related Profiles. PMID: 30300403
  10. Berhanu RH, Schnippel K, Kularatne R, Firnhaber C, Jacobson KR, Horsburgh CR, Lippincott CK. Can patients afford the cost of treatment for multidrug-resistant tuberculosis in Ethiopia? Int J Tuberc Lung Dis. 2018 08 01; 22(8):358-362.View Related Profiles. PMID: 29991400
Showing 10 of 35 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 35 publications over 8 distinct years, with a maximum of 11 publications in 2016


Contact for Mentoring:

801 Massachusetts Avenue
Boston MA 02118
Google Map

Berhanu's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department